Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

1. Usmani, S.Z.
2. Quach, H.
3. Mateos, M.-V.
4. Landgren, O.
5. Leleu, X.
6. Siegel, D.
7. Weisel, K.
8. Shu, X.
9. Li, C.
10. Dimopoulos, M.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1182/BLOODADVANCES.2023010026 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus